TMEM177: A Transmembrane Protein177 as a Potential Drug Target and Biomarker

Target Name: TMEM177

NCBI ID: G80775

TMEM177

Other Name(s): Transmembrane protein 177 | TMEM177 variant 1 | TM177_HUMAN | Transmembrane protein 177, transcript variant 1 | transmembrane protein 177

TMEM177: A Transmembrane Protein177 as a Potential Drug Target and Biomarker

Introduction

TMEM177 (Transmembrane protein 177) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It plays a critical role in cell signaling, specifically in the regulation of ion channels and the production of neurotransmitters. The loss of TMEM177 has been associated with various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy.

Recent studies have suggested that TMEM177 may have potential as a drug target or biomarker for various diseases. In this article, we will explore the biology and potential therapeutic applications of TMEM177.

The Biology of TMEM177

TMEM177 is a member of the transmembrane protein (TM) family, which includes a variety of proteins that span the cell membrane and regulate the movement of ions and molecules. TMEM177 is composed of 120 amino acids and has a calculated molecular weight of 18.5 kDa. It has a characteristic transmembrane domain, which consists of a catalytic site, a transmembrane segment, and an intramembrane segment. The transmembrane domain is responsible for the protein's unique structure and function.

TMEM177 is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is highly expressed in the brain, where it is found in the postsynaptic density of dendrites, the cell body, and the axon. TMEM177 is also expressed in other tissues, including the heart, where it is found in the intercellular junctions of cardiac muscle cells.

Potential Therapeutic Applications of TMEM177

Several studies have suggested that TMEM177 may have potential as a drug target or biomarker for various diseases.

1. Alzheimer's Disease:

Several studies have suggested that TMEM177 may be involved in the development and progression of Alzheimer's disease. The loss of TMEM177 has been observed in the brains of individuals with Alzheimer's disease, and inhibition of TMEM177 has been shown to protect against the neurotoxicity of beta-amyloid peptides in rat models of Alzheimer's disease.

2. Parkinson's Disease:

Parkinson's disease is a neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain. TMEM177 has been suggested to be involved in the regulation of dopamine release and may play a role in the development and progression of Parkinson's disease.

3. Epilepsy:

Epilepsy is a neurological disorder that is characterized by the unpredictable and sometimes recurrent episodes of electrical activity in the brain. TMEM177 has been suggested to be involved in the regulation of ion channels and the production of neurotransmitters, which may be important in the pathophysiology of epilepsy.

Conclusion

In conclusion, TMEM177 is a transmembrane protein that is expressed in various tissues of the body. Its unique structure and function make it a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. The potential therapeutic applications of TMEM177 make it an attractive target for future research and clinical development.

Protein Name: Transmembrane Protein 177

Functions: Plays a role in the early steps of cytochrome c oxidase subunit II (MT-CO2/COX2) maturation and is required for the stabilization of COX20 and the newly synthesized MT-CO2/COX2 protein

The "TMEM177 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM177 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets